Basic Information
Link Immunotherapeutics Develops Next-Generation T Cell Engager Therapies Aimed at Treating a Wide Range of Tumor Indications. The Company Designs Novel, Highly Developable Immunotherapies with Greater Selectivity for Tumors Over Normal Tissues, More Complete T Cell Activation, Offering Patients Enhanced Safety and More Durable Cancer Responses.
Link Immunotherapeutics, Inc.
Seattle,Washington,United States of America
15~50 people
January 01, 2019
--